Pluristem Therapeutics (PSTI) in Licensing Agreement with TES Holdings

 

Pluristem Therapeutics Inc. (Nasdaq: PSTI) today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic diseases with placental cell therapy rounding out the Company’s IP coverage. This license follows Pluristem’s recent announcement that the Japan Patent Office granted the Company two key patents addressing three-dimensional methods for expanding placental and adipose cells, and specified cell therapies produced from placental tissue using these methods.

Subscribe to get the latest news